Video

Dr. Talley on “landmark study” of investigational oral treatment for complicated UTIs

Author(s):

Urology Times staff

“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.

In this video, Angela Talley, MD, discusses next steps and the take-home message for the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.

Related Videos
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Daniel Carson, MD, MS, answers a question during a Zoom video interview
Benjamin Pockros, MD, MBA, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
Related Content
Crystal light - stock.adobe.com
March 4th 2022

Efficacy of batiraxcept/cabozantinib combo in clear cell RCC: Updated results

Janelle Hart
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022

Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer

Janelle Hart
To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022

How appropriate use criteria for PSMA-PET imaging optimize patient care

Janelle Hart
In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Chee summarizes latest Optilume data in patients with urethral strictures
November 9th 2021

Dr. Chee summarizes latest Optilume data in patients with urethral strictures

Urology Times staff
"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.
Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer
December 16th 2020

Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer

Urology Times staff
Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020

Dr. Padmanabhan discusses impact of COVID-19

Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
© 2024 MJH Life Sciences

All rights reserved.